EMD Serono, the biopharmaceutical division of Merck KGaA, of Darmstadt, Germany, the Institute of Cancer Research (ICR) and the Wellcome Trust, London, jointly announced a co-development and license agreement that builds on two independent research programs at both the ICR and EMD Serono to identify inhibitors of tankyrase, an enzyme of the poly (ADP-ribose) polymerase family.